UAB 1018/TBCRC 011; Bicalutamide for the Treatment of Androgen Receptor Positive (AR(+), Estrogen Receptor Negative, Progesterone Receptor Negative (ER(-)/PR(-), Metastatic Breast Cancer Patients: A Phase II Feasibility Study

Grant

Date/time Interval

  • July 1, 2009 - August 15, 2015
  • Total Award Amount

  • 28600.00
  • Direct Costs

  • 26000.00
  • Sponsor Award Id

  • 2001102334
  • Contributor

  • Nabell M.D., Lisle   Investigator